Xie Richard Z, Malik Erica deFur, Linthicum Mark T, Bright Jennifer L
Innovation and Value Initiative, Alexandria, Virginia, USA.
Pharmacoeconomics. 2021 Jun;39(6):631-638. doi: 10.1007/s40273-021-01036-3. Epub 2021 May 13.
While evidence generated from health economic (HE) models is being used more commonly in health technology assessment (HTA) in the US, it is not consistently adopted by different stakeholder groups or across therapeutic areas. We hypothesize that actively engaging with multiple stakeholder groups throughout the model development process may result in models more widely considered by decision makers. To test this hypothesis, the Innovation and Value Initiative has launched a modeling effort to build an open-source HE model focusing on the disease state 'major depressive disorder'. A 20-member advisory group has been formed with representatives from patients, employers, clinicians, innovators, payers, and researchers to guide the model development process. While this effort is still in the early stages, the ongoing stakeholder engagement effort has yielded valuable insights that inform the model design. We have also identified several challenges to implementing this new approach. Our early findings suggest that the stakeholder engagement approach to HE model development has the potential to improve HTA in the US.
虽然在美国,卫生经济(HE)模型产生的证据在卫生技术评估(HTA)中越来越普遍地被使用,但不同利益相关者群体或不同治疗领域并未一致采用。我们假设,在整个模型开发过程中积极与多个利益相关者群体互动,可能会使模型得到决策者更广泛的考虑。为了验证这一假设,创新与价值倡议组织发起了一项建模工作,以构建一个专注于“重度抑郁症”疾病状态的开源卫生经济模型。一个由20名成员组成的咨询小组已经成立,成员包括患者、雇主、临床医生、创新者、支付方和研究人员的代表,以指导模型开发过程。虽然这项工作仍处于早期阶段,但正在进行的利益相关者参与工作已经产生了为模型设计提供信息的宝贵见解。我们还确定了实施这种新方法的几个挑战。我们的早期研究结果表明,卫生经济模型开发的利益相关者参与方法有可能改善美国的卫生技术评估。